Keywords
How to Cite
Abstract
Prostate cancer is the most common cancer among men over 60 years of age. Treatment of prostate cancer includes surgery, hormone therapy or radiotherapy. Radiotherapy is the least invasive treatment, often combined with other methods or is used alone. Ultrahypofractionated stereotactic radiotherapy (SBRT), which was the subject of this study, in the Greater Poland Cancer Center was carried out on the Cyberknife System.
Treatment tolerance can be defined as the degree of occurrence of complications after the therapy. If the side effects of treatment are rare, they are weak and do not reduce the patient's quality of life - the tolerance of treatment is good.
This study presented the results of tolerance on ultrahypofractionated radiotherapy treatment in patients with prostate cancer treated at the Radiation Oncology Department I in Greater Poland Cancer. The patients were irradiated on the Cyberknife using the SBRT method with a dose of 7.0 Gy -7.25 Gy, administered 5 times every other day, up to a total dose of 35.0 Gy - 36.25Gy. Assessment of tolerability of therapy was established on the basis of patient-filled surveys of the IPSS completed in the pre-treatment period, after the last fraction, 1 and 24 months after the end of the RT. Average age patients was 69 years, the average PSA score was 9, and the average Gleason score was 6.
Based on our results all patients had a worsening of the urinary tract symptoms during the last irradiation fraction and one month after the end of treatment, while at 24 months after RT, this level compared with the pre-treatment outcome. This phenomenon is associated with the occurrence of the typical radiation reaction for radiotherapy. The results of the study confirm good tolerance of SBRT which coincides with the current state of knowledge and suggest that SBRT due to shorter treatment time, equally high efficacy and good tolerance, could in the future replace conventional radiotherapy schedules in treatment of prostate cancer.
References
Krajowy Rejestr Nowotworów- Gruczoł krokowy. http://onkologia.org.pl/rak-gruczolu-krokowego/.
Global Cancer Observatory, Globocan 2018; https://gco.iarc.fr/today/home.
Ricco A, Manahan G, Lanciano R. The Comparison of Stereotactic Body Radiation Therapy and Intensity-Modulated Radiation Therapy for Prostate Cancer by NCCN Risk Groups. Frontiers in Oncology 2016; 6:184. DOI: https://doi.org/10.3389/fonc.2016.00184
Głowacki G, Bodusz D, Majewski W. Frakcjonowana radioterapia stereotaktyczna CyberKnifeTM chorych na raka gruczołu krokowego. Journal of Oncology 2012;62(4): 274–282.
King C. Lehmann J. Adler J. Hai J. CyberKnife Radiotherapy for Localized Prostate Cancer: Rationale and Technical Feasibility. Technol Ca Res Treat 2003; 2: 25-29. DOI: https://doi.org/10.1177/153303460300200104
Michalewska J. Odczyny popromienne w radioterapii oraz popromienne zapalenie skóry. Zeszyty Naukowe WCO, Letters in Oncology Science 2017;14(4):104-109.
Scott C, Morgan MD, MSc, FRCPC, Karen Hoffman MD, MHSc, MPH, D. Andrew Loblaw MD, MSc, FRCPC, FASCO. Hypofractionated Radiation Therapy for Localized Prostate Cancer: Executive Summary of an ASTRO, ASCO, and AUA Evidence-Based Guideline. Pract Radiat Oncol 2018: 8;354-360.
Katz A. Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: A Ten-Year Analysis. Cureus 2017;9(9): e1668. DOI: https://doi.org/10.7759/cureus.1668
Cihan Y. The role and importance of SBRT in prostate cancer. Int Braz J Urol 2018;44:1272–1274. DOI: https://doi.org/10.1590/s1677-5538.ibju.2018.0484
Madsen BL, Hsi RA, Pham HT, Fowler JF, Esagui L, Corman J. Stereotactic hypofractionated accurate radiotherapy of the prostate (sharp). 33.5 Gy in five fractions for localized disease: first clinical trial results. Int J Radiat Oncol Biol Phys 2007;67(4):1099–105. DOI: https://doi.org/10.1016/j.ijrobp.2006.10.050
Friedland JL, Freeman DE, Masterson-McGary ME, Spellberg DM. Stereotactic body radiotherapy: an emerging treatment approach for localized prostate cancer. Technol Cancer Res Treat 2009;8(5):387–92. DOI: https://doi.org/10.1177/153303460900800509
Katz AJ, Santoro M, Ashley R, Diblasio F,Witten M. Stereotactic body ra-diotherapy for organ-confined prostate cancer. BMC Urol 2010;10:1. DOI: https://doi.org/10.1186/1471-2490-10-1
King C. Stereotactic body radiotherapy for prostate cancer: current results of a phase II trial. Front Radiat Ther Oncol 2011;43:428–37. DOI: https://doi.org/10.1159/000322507
King CR, Brooks JD, Gill, et al. Stereotactic body radiotherapy for localized prostate cancer: interim results of a prospective phase II clinical trial. Int J Radiat Oncol Biol Phys 2009;73:1043–8. DOI: https://doi.org/10.1016/j.ijrobp.2008.05.059
Lartigau E. Stereotactic body radiotherapy. BMJ 2011;343:24. DOI: https://doi.org/10.1136/bmj.d4286